Founders Financial Securities’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$272K Buy
11,306
+125
+1% +$3.27K 0.01% 485
2026
Q1
$304K Sell
11,181
-326
-3% -$8.68K 0.02% 449
2025
Q4
$287K Buy
11,507
+1,459
+15% +$36.8K 0.02% 482
2025
Q3
$256K Sell
10,048
-2,108
-17% -$52K 0.02% 443
2025
Q2
$295K Sell
12,156
-1,882
-13% -$43.9K 0.02% 416
2025
Q1
$324K Buy
14,038
+2,263
+19% +$59.2K 0.03% 382
2024
Q4
$312K Sell
11,775
-1,759
-13% -$47.7K 0.03% 369
2024
Q3
$392K Sell
13,534
-2,880
-18% -$84K 0.04% 305
2024
Q2
$459K Buy
16,414
+2,558
+18% +$70.4K 0.04% 298
2024
Q1
$385K Sell
13,856
-51,071
-79% -$1.42M 0.04% 290
2023
Q4
$1.87M Sell
64,927
-760
-1% -$23K 0.21% 94
2023
Q3
$2.18M Buy
65,687
+33,330
+103% +$1.18M 0.28% 72
2023
Q2
$1.19M Buy
32,357
+2,298
+8% +$89.4K 0.16% 125
2023
Q1
$1.23M Buy
30,059
+905
+3% +$39.1K 0.18% 113
2022
Q4
$1.49M Buy
29,154
+2,101
+8% +$101K 0.24% 90
2022
Q3
$1.18M Sell
27,053
-223
-0.8% -$10.8K 0.21% 99
2022
Q2
$1.43M Buy
27,276
+1,173
+4% +$59.8K 0.28% 75
2022
Q1
$1.35M Buy
26,103
+739
+3% +$38.3K 0.24% 89
2021
Q4
$1.5M Buy
25,364
+447
+2% +$22.1K 0.27% 79
2021
Q3
$1.07M Buy
24,917
+550
+2% +$24.4K 0.22% 98
2021
Q2
$954K Buy
24,367
+1,469
+6% +$57.1K 0.19% 110
2021
Q1
$830K Buy
22,898
+1,520
+7% +$54K 0.19% 108
2020
Q4
$787K Buy
21,378
+5,729
+37% +$210K 0.19% 99
2020
Q3
$545K Sell
15,649
-1,461
-9% -$51.2K 0.17% 84
2020
Q2
$546K Buy
17,110
+4,998
+41% +$170K 0.18% 95
2020
Q1
$375K Buy
12,112
+1,912
+19% +$65.2K 0.14% 83
2019
Q4
$379K Buy
10,200
+1,668
+20% +$59.4K 0.13% 87
2019
Q3
$291K Buy
8,532
+1,414
+20% +$51.4K 0.09% 107
2019
Q2
$293K Buy
7,118
+389
+6% +$15.4K 0.1% 101
2019
Q1
$271K Buy
6,729
+1,248
+23% +$50K 0.09% 101
2018
Q4
$227K Buy
+5,481
New +$228K 0.08% 96

Other funds holding PFE

Founders Financial Securities's PFE Position: Q2 2026 in Review

Founders Financial Securities increased its Pfizer (PFE) stake by 1.1% in Q2 2026, buying an estimated $3.27K and bringing the position to 11,306 shares worth $272K. The position accounts for 0.01% of the portfolio, ranked #485.

Founders Financial Securities first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.18M in Q3 2023. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Founders Financial Securities held 11,306 shares of Pfizer worth $272K as of Q2 2026.
  • Founders Financial Securities bought 125 Pfizer shares in Q2 2026, an estimated $3.27K.
  • Pfizer made up 0.01% of Founders Financial Securities's portfolio in Q2 2026, its #485 holding.
  • Founders Financial Securities first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
  • Founders Financial Securities's Pfizer position peaked at $2.18M in Q3 2023.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Founders Financial Securities's 13F filing for Q2 2026, filed 31 Jul 2026.